HIV: Islatravir Clinical Program Overview

Islatravir (formerly MK-8591, EFdA) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor. Islatravir is currently being evaluated for the treatment of HIV-1 infection in combination with other antiretrovirals, as well as for pre-exposure prophylaxis (PrEP) of HIV-1 infection as a single agent across a variety of formulations.

Please find a Islatravir Clinical Program Overviw at the following link

Link: https://www.merck.com/wp-content/uploads/sites/5/2021/07/ISL-Pipeline-Document-7-7-21.pdf